Theratechnologies (TSE:TH) Price Target Cut to C$7.00

Theratechnologies (TSE:TH) had its price objective cut by research analysts at Mackie from C$8.15 to C$7.00 in a research report issued on Friday, BayStreet.CA reports. The brokerage currently has a “hold” rating on the stock. Mackie’s price objective would suggest a potential upside of 19.66% from the stock’s current price.

TH has been the subject of a number of other reports. Stifel Nicolaus initiated coverage on shares of Theratechnologies in a research report on Tuesday, May 14th. They set a “buy” rating and a C$15.00 price target for the company. Royal Bank of Canada set a $184.00 price target on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, July 3rd. Finally, National Bank Financial raised their price target on shares of Wesdome Gold Mines from C$6.00 to C$6.25 and gave the stock an “outperform” rating in a research report on Friday. Two research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of C$9.56.

TH opened at C$5.85 on Friday. Theratechnologies has a 12-month low of C$5.17 and a 12-month high of C$11.45. The company has a quick ratio of 1.97, a current ratio of 2.46 and a debt-to-equity ratio of 145.32. The stock has a market cap of $449.88 million and a price-to-earnings ratio of -119.39. The stock’s 50 day simple moving average is C$6.75.

Large investors have recently bought and sold shares of the company. Virtu Financial LLC purchased a new position in shares of Theratechnologies during the 1st quarter valued at approximately $96,000. Mesirow Financial Investment Management Inc. purchased a new position in shares of Theratechnologies during the 1st quarter valued at approximately $328,000. Monarch Partners Asset Management LLC purchased a new position in shares of Theratechnologies during the 1st quarter valued at approximately $4,256,000. Finally, LLBH Private Wealth Management LLC purchased a new position in shares of Theratechnologies during the 1st quarter valued at approximately $1,735,000.

About Theratechnologies

Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States.

Featured Story: The limitations of an equal weight rating

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.